{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:34:14Z","timestamp":1789778054731,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The Systemic Immune-Inflammatory Index (SII) is a comprehensive indicator reflecting immune response and disease burden. However, its significance in immune checkpoint inhibitor-related pneumonitis (CIP) in cases of non-small cell lung cancer (NSCLC) remains poorly explored. This study evaluated the association between SII and the incidence, severity, and prognostic effects of CIP in NSCLC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis involved 215 NSCLC patients receiving immune checkpoint inhibitor (ICI) therapy, of whom 35 developed CIP while 180 did not. Baseline clinical characteristics and dynamic changes in peripheral blood biochemical markers were analyzed. Risk factors associated with the onset and severity of CIP were assessed, along with the diagnostic application of the SII for CIP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariate logistic regression identified smoking history (odds ratio [OR]: 3.23; <jats:italic>p<\/jats:italic> = 0.01), pre-existing lung disease (OR: 3.36; <jats:italic>p<\/jats:italic> &amp;lt; 0.01), squamous cell carcinoma (OR: 2.39; <jats:italic>p<\/jats:italic> = 0.03), and combined ICI therapy (OR: 4.77; <jats:italic>p<\/jats:italic> &amp;lt; 0.01) as independent risk factors for CIP onset. SII was also identified as independently predictive of severe CIP (OR: 6.35; <jats:italic>p<\/jats:italic> = 0.04). Receiver operating characteristic (ROC) curves demonstrated that SII had moderate accuracy for diagnosing CIP (area under the curve [AUC]: 0.63) and high diagnostic accuracy for severe CIP (AUC: 0.81). Multivariate Cox regression also showed that severe CIP was substantially related to reduced overall survival (OS) relative to mild CIP (hazard ratio [HR]: 0.06, 95% confidence interval [CI]: 0.01\u20130.52; <jats:italic>p<\/jats:italic> = 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results suggested the potential of SII as an indicator for diagnosing the presence and severity of CIP. Elevated SII levels were independently associated with the development of severe CIP, which, in turn, emerged as a key prognostic factor influencing overall survival in affected patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1596223","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:11:07Z","timestamp":1749701467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Mengyao","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangqian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15170","article-title":"Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data","volume":"15","author":"Bi","year":"2023","journal-title":"Thorac Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.877594","article-title":"Immunotherapy in non-small cell lung cancer: Past, present, and future directions","volume":"12","author":"Punekar","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunotherap Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","article-title":"Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: Current understanding in characteristics, diagnosis, and management","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00262-024-03834-y","article-title":"Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12890-021-01523-5","article-title":"Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"21","author":"Nishiyama","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2021_069","article-title":"Comparison of inflammation markers with prediction scores in patients with community-acquired pneumonia","volume":"122","author":"Acar","year":"2021","journal-title":"Bratisl Lek Listy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/IJGM.S314393","article-title":"Systemic immune-inflammation index for predicting the prognosis of critically ill patients with acute pancreatitis","volume":"14","author":"Zhang","year":"2021","journal-title":"Int J Gen Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000001037","article-title":"Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease","volume":"32","author":"Liu","year":"2021","journal-title":"Coron Artery Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212998","article-title":"Systemic inflammation index, disease severity, and mortality in patients with COVID-19: A systematic review and meta-analysis","volume":"14","author":"Mangoni","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3892\/ol.2024.14243","article-title":"Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non\u2212small cell lung cancer treated with immunotherapy","volume":"27","author":"Ito","year":"2024","journal-title":"Oncol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1138305","article-title":"Baseline risk factors associated with immune related adverse events and atezolizumab","volume":"13","author":"Madjar","year":"2023","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000526141","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: A systemic review and meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration"},{"key":"B22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12890-022-02127-3","article-title":"Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia","volume":"22","author":"Li","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tlcr-22-72","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer","volume":"11","author":"Chao","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00262-024-03792-5","article-title":"Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: Clinical utility of subcategorizing interstitial lung abnormalities","volume":"73","author":"Kikuchi","year":"2024","journal-title":"Cancer Immunology Immunotherapy : CII"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: Clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: An opportunity for combination with cytokines","volume":"7","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101227","article-title":"Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy","volume":"68","author":"Iriarte-Gahete","year":"2024","journal-title":"Blood Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1145143","article-title":"Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e23964","DOI":"10.1002\/jcla.23964","article-title":"Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis","volume":"35","author":"Wu","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S451466","article-title":"The clinical value of systemic immune inflammation index (SII) in predicting the severity of hospitalized children with mycoplasma pneumoniae pneumonia: A retrospective study","volume":"17","author":"Wang","year":"2024","journal-title":"Int J Gen Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15964","article-title":"Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy","volume":"114","author":"Huai","year":"2023","journal-title":"Cancer Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0133","article-title":"Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: Systemic review and meta-analysis","volume":"14","author":"Tian","year":"2022","journal-title":"Immunotherapy"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, thrombo-inflammation, and cancer: Collaborating with the enemy","volume":"10","author":"Palacios-Acedo","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00654","article-title":"Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs)","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thorac Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103176","article-title":"Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives","volume":"157","author":"Marinelli","year":"2021","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:11:08Z","timestamp":1749701468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1596223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1596223"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1596223","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1596223"}}